(NASDAQ: KURA) Kura Oncology's forecast annual revenue growth rate of 53.52% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.21%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.36%.
Kura Oncology's revenue in 2026 is $67,482,000.On average, 17 Wall Street analysts forecast KURA's revenue for 2026 to be $9,674,758,503, with the lowest KURA revenue forecast at $4,328,158,191, and the highest KURA revenue forecast at $29,298,981,060. On average, 16 Wall Street analysts forecast KURA's revenue for 2027 to be $15,295,181,068, with the lowest KURA revenue forecast at $5,237,071,411, and the highest KURA revenue forecast at $26,031,663,275.
In 2028, KURA is forecast to generate $21,729,120,714 in revenue, with the lowest revenue forecast at $7,851,278,958 and the highest revenue forecast at $39,494,001,844.